We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

65 hedge funds and large institutions have $36.7M invested in Matinas BioPharma in 2020 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 12

7% more capital invested

Capital invested by funds: $34.4M → $36.7M (+$2.31M)

0.1% less ownership

Funds ownership: 0.58% → 0.48% (-0.1%)

4% less funds holding

Funds holding: 68 → 65 (-3)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

Holders
65
Holders Change
-3
Holders Change %
-4.41%
% of All Funds
1.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
16
Reduced
12
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
+$467K
2
CIBC Private Wealth Group
CIBC Private Wealth Group
Georgia
+$460K
3
BCM
Bridgeway Capital Management
Texas
+$288K
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$225K
5
California Public Employees Retirement System
California Public Employees Retirement System
California
+$207K

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$5.04M
2
BBA
Baker Bros. Advisors
New York
-$1.27M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$775K
4
Renaissance Technologies
Renaissance Technologies
New York
-$581K
5
Morgan Stanley
Morgan Stanley
New York
-$542K
Name Holding Trade Value Shares
Change 		Change in
Stake
ARTA
51
A.R.T. Advisors
New York
$10K +$10.2K +267 New
Franklin Resources
52
Franklin Resources
California
$9K – – –
CFS
53
CRA Financial Services
New Jersey
$8K – – –
FAIM
54
Financial Advocates Investment Management
Washington
$8K – – –
FC
55
Fore Capital
New York
$8K – – –
PA
56
Planning Alternatives
Michigan
$8K – – –
IFG
57
Investors Financial Group
Minnesota
$8K +$7.67K +200 New
Morgan Stanley
58
Morgan Stanley
New York
$6K -$542K -14,137 -99%
Osaic Holdings
59
Osaic Holdings
Arizona
$5K – – –
HFM
60
Hartford Financial Management
Connecticut
$2K – – –
SPIA
61
Steward Partners Investment Advisory
New York
$2K – – –
CAL
62
Capital Analysts LLC
Pennsylvania
$1K – – –
BNP Paribas Financial Markets
63
BNP Paribas Financial Markets
France
$19 – – –
Susquehanna International Group
64
Susquehanna International Group
Pennsylvania
– -$775K -25,828 Closed
Bank of Montreal
65
Bank of Montreal
Ontario, Canada
– -$182K -6,583 Closed
Goldman Sachs
66
Goldman Sachs
New York
– -$146K -4,861 Closed
SG Americas Securities
67
SG Americas Securities
New York
– -$100K -3,347 Closed
HF
68
HRT Financial
New York
– -$43K -1,463 Closed
Bank of America
69
Bank of America
North Carolina
– -$25K -824 Closed
JG
70
Jefferies Group
New York
– -$22K -744 Closed
AGM
71
Alpine Global Management
New York
– -$12K -406 Closed
TSS
72
Two Sigma Securities
New York
– -$6K -217 Closed
AIC
73
Ameritas Investment Company
Nebraska
– -$3K -112 Closed
1 2
3

MTNB Hedge Fund Activity: Q2 2020 in Review

65 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2020, worth a combined $36.7M — up 6.7% from $34.4M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of MTNB and 8 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 16 added.

The largest buyer was Two Sigma Investments, adding an estimated $467K. The largest seller was Victory Capital Management, cutting an estimated $5.04M.

  • 65 institutional investors held Matinas BioPharma (MTNB) as of Q2 2020, down from 68 in Q1 2020.
  • Funds reported $36.7M of Matinas BioPharma stock for Q2 2020, up 6.7% quarter-over-quarter.
  • 8 funds opened new Matinas BioPharma positions in Q2 2020 and 11 closed out, a net change of -3 holders.
  • The largest Matinas BioPharma buyer in Q2 2020 was Two Sigma Investments, an estimated $467K added.
  • The largest Matinas BioPharma seller in Q2 2020 was Victory Capital Management, an estimated $5.04M sold.

Based on aggregated 13F filings for Q2 2020.